Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michiel van de Sande

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
Future Oncology (London, England)|July 24, 2020
Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumorHans Gelderblom, Michiel van de Sande
Journal of the American Academy of Orthopaedic Surgeons. Global Research & Reviews|November 6, 2020
Management of Tenosynovial Giant Cell Tumor: A Neoplastic and Inflammatory DiseaseJohn H Healey, Nicholas M Bernthal, Michiel van de Sande
Current Opinion in Oncology|June 17, 2020
Current concepts in the treatment of giant cell tumour of boneLizz van der Heijden, Sander Dijkstra, Michiel van de Sande, et al.
Scientific Reports|March 21, 2024
Evaluation of computed tomography artefacts of carbon-fiber and titanium implants in patients with spinal oligometastatic disease undergoing stereotactic ablative radiotherapyZeger Rijs, Khandkar Ali Kawsar, Priyanshu Saha, et al.
The Journal of Bone and Joint Surgery. American Volume|July 19, 2023
Operative Treatment and Outcomes of Pediatric Patients with an Extremity Bone Tumor: A Secondary Analysis of the PARITY Trial DataAnthony Bozzo, Caleb M Yeung, Michiel Van De Sande, et al.
BMJ Open|March 5, 2022
Disease progression in osteosarcoma: a multistate model for the EURAMOS-1 (European and American Osteosarcoma Study) randomised clinical trialAudinga-Dea Hazewinkel, Carlo Lancia, Jakob Anninga, et al.
International Orthopaedics|March 7, 2015
High-grade soft tissue sarcomas of the extremities: surgical margins influence only local recurrence not overall survivalJulie Willeumier, Marta Fiocco, Remi Nout, et al.
European Journal of Cancer (Oxford, England : 1990)|September 13, 2025
Pharmacokinetics and pharmacodynamics of an anti-CSF1 receptor antibody in the intra-articular treatment of tenosynovial giant cell tumorMichiel van de Sande, Kirk Johnson, Kirsten van Langevelde, et al.
JB & JS Open Access|February 24, 2025
Periprosthetic Joint Infection Surrounding Lower-Extremity Endoprostheses After Tumor Resection: Causative Microorganisms, Effectiveness of DAIR, and Risk Factors for Treatment FailurePhilip Sanders, Henk Scheper, Robert van der Wal, et al.
Future Oncology (London, England)|June 23, 2025
The economic and humanistic burden of tenosynovial giant cell tumor: a targeted literature reviewMichiel van de Sande, Jean-Yves Blay, William Tap, et al.
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Future Oncology (London, England)|July 24, 2020
Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumorHans Gelderblom, Michiel van de Sande
Journal of the American Academy of Orthopaedic Surgeons. Global Research & Reviews|November 6, 2020
Management of Tenosynovial Giant Cell Tumor: A Neoplastic and Inflammatory DiseaseJohn H Healey, Nicholas M Bernthal, Michiel van de Sande
Current Opinion in Oncology|June 17, 2020
Current concepts in the treatment of giant cell tumour of boneLizz van der Heijden, Sander Dijkstra, Michiel van de Sande, et al.
Scientific Reports|March 21, 2024
Evaluation of computed tomography artefacts of carbon-fiber and titanium implants in patients with spinal oligometastatic disease undergoing stereotactic ablative radiotherapyZeger Rijs, Khandkar Ali Kawsar, Priyanshu Saha, et al.
The Journal of Bone and Joint Surgery. American Volume|July 19, 2023
Operative Treatment and Outcomes of Pediatric Patients with an Extremity Bone Tumor: A Secondary Analysis of the PARITY Trial DataAnthony Bozzo, Caleb M Yeung, Michiel Van De Sande, et al.
BMJ Open|March 5, 2022
Disease progression in osteosarcoma: a multistate model for the EURAMOS-1 (European and American Osteosarcoma Study) randomised clinical trialAudinga-Dea Hazewinkel, Carlo Lancia, Jakob Anninga, et al.
International Orthopaedics|March 7, 2015
High-grade soft tissue sarcomas of the extremities: surgical margins influence only local recurrence not overall survivalJulie Willeumier, Marta Fiocco, Remi Nout, et al.
European Journal of Cancer (Oxford, England : 1990)|September 13, 2025
Pharmacokinetics and pharmacodynamics of an anti-CSF1 receptor antibody in the intra-articular treatment of tenosynovial giant cell tumorMichiel van de Sande, Kirk Johnson, Kirsten van Langevelde, et al.
JB & JS Open Access|February 24, 2025
Periprosthetic Joint Infection Surrounding Lower-Extremity Endoprostheses After Tumor Resection: Causative Microorganisms, Effectiveness of DAIR, and Risk Factors for Treatment FailurePhilip Sanders, Henk Scheper, Robert van der Wal, et al.
Future Oncology (London, England)|June 23, 2025
The economic and humanistic burden of tenosynovial giant cell tumor: a targeted literature reviewMichiel van de Sande, Jean-Yves Blay, William Tap, et al.
Pageof 4